Introduction
The first Staphylococcus aureus with reduced susceptibility to vancomycin was described by Hiramatsu et al. 1 in 1997. The organism, called Mu50, had an MIC of vancomycin of 8 mg/L. At that time, the CLSI defined staphylococci for which the MIC of vancomycin was ≤4 mg/L as susceptible, isolates for which the MIC was 8 -16 mg/L as intermediate and those for which the MIC was ≥32 mg/L as resistant. 2 Therefore, the Mu50 isolate was defined as a vancomycin-(or glycopeptide-)intermediate S. aureus (VISA). Concomitantly, the same author reported a second S. aureus, called Mu3, responsible for vancomycin treatment failure in an adult patient with pneumonia. 3 Although the vancomycin MIC for this isolate was 4 mg/L and the isolate was formally considered as susceptible at the time, Mu3 contained VISA subpopulations (≤10 26 cfu) that grew in the presence of 5-9 mg/L vancomycin and were not detected by standard drug-susceptibility testing. The term heteroresistant VISA (hVISA) was coined to define the Mu3 phenotype. Since then, a number of cases of VISA and hVISA have been described worldwide 4 and have been associated with vancomycin treatment failures both in animal experiments 5 -7 and in humans. 7 -9 Revised CLSI breakpoints now classify isolates with an MIC between 4 and 8 mg/L of vancomycin as VISA. 2 VISA and hVISA are different from fully vancomycinresistant S. aureus (VRSA; MIC ≥32 mg/L), which have been reported in the USA since 2002. 10, 11 In VRSA, vancomycin resistance is due to the acquisition of the vanA determinant, which also mediates high-level resistance to vancomycin in enterococci, 12 and is situated on a conjugative transposon. 13, 14 In contrast, the resistance phenotype in VISA and hVISA is associated with a thickened cell wall 15 and various chromosomal mutations that affect metabolic and cell wall synthesis pathways. 16 -21 Because of their relatively low vancomycin MIC, hVISA are notoriously difficult to identify by routine laboratory procedures. 4 For example, for Mu3 the rate of resistant subpopulations at a vancomycin concentration of 8 mg/L is in the order of 10 26 , which is one to two orders of magnitude below the detection level of standard susceptibility tests (which use inoculum sizes of 10 4 -5 cfu). Moreover, the hVISA phenotype is reputed to be unstable, due to the overgrowth of slow-growing resistant subpopulations by faster-growing susceptible ones in the absence of the drug. 22 This is somewhat reminiscent of the early times of methicillin-resistant S. aureus (MRSA), where heterogeneous expression of methicillin resistance passed undetected by routine laboratory testing, and the organisms were falsely reported as methicillin susceptible. 23 Vancomycin treatment failures of S. aureus infections have been reported repeatedly, even before the description of VISA and hVISA. 24 These were often attributed to the slow bactericidal effect of the drug 24 and/or to the severity of the patients' underlying conditions. 25 However, knowing the difficulty of hVISA and VISA detection, the question now arises as to whether some of these vancomycin failures were not due to the lack of identification of such organisms. The present experiments addressed this hypothesis both by studying the natural history of hVISA and VISA emergence during vancomycin treatment of experimental endocarditis and by testing the ability of standard culture-based laboratory procedures to detect the emerging hVISA or VISA. We also examined the ability of such selected hVISA or VISA to persist after treatment discontinuation.
Materials and methods

Microorganisms and growth conditions
A vancomycin-susceptible MRSA (strain M1V2, vancomycin MIC of 2 mg/L) recovered from a patient with endocarditis was used in animal experiments. For certain experiments, strain M1V2 was passaged with vancomycin in the laboratory, as described previously, 26 to generate the isogenic VISA M1V8 (vancomycin MIC of 8 mg/L). Additional reference strains used for susceptibility testing and agr typing included S. aureus ATCC 29213 (vancomycin susceptible), hVISA Mu3, VISA Mu50 (both generously provided by K. Hiramatsu, Juntendo University, Tokyo, Japan), S. aureus RN6390 (agr group I), RN6607 (agr group II), RN8465 (agr group III), RN4850 (agr group IV) and RN6911 (null agr) (all generously provided by F. Vandenesch, Lyon, France). 27, 28 Unless otherwise stated, all the organisms were grown at 378C either on brain heart infusion (BHI) agar plates (Becton Dickinson, Sparks, MD, USA) or in BHI broth (Becton Dickinson) with shaking at 120 rpm. Stocks were kept at 2708C in BHI broth supplemented with 10% (v/v) glycerol.
Bacterial typing
Clonal identity between the parent M1V2 and S. aureus colonies recovered from vegetations of rats with treatment failures was assessed by PFGE using a CHEF-DR II apparatus (Bio-Rad Laboratories, Hercules, MA, USA), as described previously. 29 The agr group of the parent and control strains was determined by PCR using previously described primers. 27, 28, 30 Antimicrobial susceptibility testing MICs were determined by the broth macrodilution method in cation-adjusted Mueller-Hinton broth (Becton Dickinson) according to CLSI standards, with an inoculum of 10 5 -10 6 cfu/mL, and by Etest on BHI agar plates, by applying an inoculum with a turbidity equivalent to that of a 2 McFarland standard. 31 The MIC was defined as the lowest concentration of antibiotic that yielded no visible growth after 24 h of incubation at 378C. Time-kill studies were performed by adding vancomycin to mid-logarithmic phase cultures at final concentrations mimicking peak (40 mg/L) and trough (5 mg/L) drug concentrations achieved in the serum of humans during therapy. Samples were removed 0, 6, 12 and 24 h after drug addition, serially diluted and spread on agar plates. Colony counts were determined after 48 h of incubation at 378C.
In vitro population analysis
Population analyses were carried out by spreading serial dilutions of an overnight culture ( 10 9 cfu/mL) of the test strains on agar plates containing arithmetic progressions of vancomycin concentrations from 1 to 8 mg/L. Colonies were counted after 48 h of incubation at 378C. Population analysis curves were drawn by plotting the numbers of colonies growing on the plates against the concentrations of vancomycin in the plates.
Production of endocarditis and installation of an infusion pump device
All animal experiments were carried out according to the Swiss Federal Act on Animal Protection. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Consumer and Veterinary Affairs Department of the State of Vaud (permit number 879.8). Induction of sterile aortic vegetations and installation of the infusion pump to deliver vancomycin were performed as previously described. 32, 33 Infective endocarditis was induced 24 h later by intravenous (iv) challenge of the animals with 0.5 mL of saline containing 10 5 cfu of the vancomycin-susceptible parent strain M1V2. This inoculum corresponded to 10 times the minimum size of bacterial inoculum producing endocarditis in ≥90% of the rats.
Vancomycin treatment of experimental endocarditis
Treatment was started 18 h after inoculation and lasted for 2 days. Treated animals received doses of vancomycin that mimicked the pharmacokinetics seen in humans following iv administration of 1 g of the drug every 12 h. 34 Control animals received saline. Rates and severity of valve infection were determined in animals killed either just before treatment onset, in order to determine the vegetation load at the start of therapy (control rats), or 8 h (early evaluation) or 72 h (late evaluation) after the end of therapy. As an additional control, a few untreated animals were followed over the entire experiment and killed in parallel to the early and late evaluation timepoints. The vegetations were dissected under sterile conditions, weighed, homogenized in 1 mL of saline, serially diluted and plated for colony counts. The limit of detection was 2 log 10 cfu/g of vegetation. 
Pharmacokinetic studies
The concentration of vancomycin in the serum of rats was determined by an agar diffusion assay with antibiotic medium 1 (Difco) and Bacillus subtilis ATCC 6633 as the indicator organism. Standard curves were determined using pooled rat serum. The limit of detection of the assay was 0.7 mg/L. The linearities of the standard curves were assessed with a regression coefficient of ≥0.994. Intraplate and interplate variations were ≤10%.
Ex vivo population analysis
The possible emergence of hVISA or VISA in animals was assessed either by direct plating of vegetation homogenates on agar containing serial dilutions of vancomycin or by plating the homogenates after overnight growth in antibiotic-free broth. For direct plating, 0.01 mL aliquots of the homogenates, plus serial dilutions of them, were used. For plating after overnight regrowth, 0.01 mL aliquots of the same homogenates were inoculated into 10 mL of drug-free broth and incubated overnight before processing as above. Colonies that grew on plates containing 8 mg/L vancomycin were picked at random and retested for vancomycin MIC.
In vitro and in vivo persistence of the vancomycin intermediate-resistant phenotype
The in vitro and in vivo persistence of subpopulations with decreased susceptibility to vancomycin was tested using a laboratory-generated VISA derivative of parent M1V2, strain M1V8. For in vitro persistence examination, stationary phase cultures of the susceptible M1V2 strain and of its vancomycin-passaged VISA derivative M1V8 (vancomycin MIC of 8 mg/L) were left to stand at 378C for 15 days. At several timepoints during this period, aliquots were removed and plated on agar containing increasing concentrations of vancomycin. To test the persistence of the VISA phenotype in vivo, animals with catheter-induced aortic vegetations were infected with either the vancomycin-susceptible M1V2 or its VISA derivative M1V8 and followed without therapy for 7 days. Animals were killed at several timepoints; their vegetations were processed as above and directly plated on vancomycin-containing agar.
Statistical analysis
The rates of valve infections of the various groups were compared by the Fisher's exact test.
Results
agr type and vancomycin susceptibility profile
Test strain M1V2 was agr group II, which is a frequent agr type associated with vancomycin-intermediate resistance and vancomycin treatment failure. 35, 36 Its basal MIC of vancomycin was 2 mg/L, as measured both by broth dilution and Etest. Accordingly, population analysis profiles indicated that the entire population of M1V2 was inhibited by 4 mg/L vancomycin and contained no resistant subpopulations (Figure 1 ). In contrast, its vancomycin-cycled derivative M1V8 had a vancomycin MIC of 8 mg/L and behaved like a true VISA in population analyses (Figure 1 ). In time -kill studies, parent M1V2 lost 2 -2.5 log 10 cfu/mL after 24 h of exposure to vancomycin concentrations mimicking peak and trough concentrations of the drug in the blood, i.e. 40 and 5 mg/L, respectively, whereas VISA M1V8 resisted killing and lost ≤1 log 10 cfu/mL at 24 h in the same conditions (data not presented).
Pharmacokinetic studies
The peak (30 min after drug injection) and trough (12 h after drug injection) concentrations (mean+SD for three to six individual animals) of vancomycin were 42.2+3.7 and 8.8+2.3 mg/L, respectively. These concentrations of vancomycin in the serum of rats were very close to the peak and trough vancomycin concentrations previously reported in the same experimental model and in humans. 26, 34 Experimental endocarditis Figure 2 depicts the natural outcome of valve infection and vancomycin therapy in rats inoculated with the susceptible parent M1V2. The median vegetation bacterial density in untreated control animals was 8.3 log 10 cfu/g at treatment onset and increased progressively to 11.3 log 10 cfu/g (left panel of Figure 2 ). In treated animals the outcome of valve infection was treatment success in 14 of 26 (54%) animals and treatment failures in 12 of 26 (46%) animals (right panel of Figure 2 ). PFGE showed the M1V2 strain used for challenge and the vegetation isolates were indistinguishable, confirming that they had the same origin (data not presented). directly at treatment onset, when vegetation bacterial densities were ,9 log 10 cfu/g (data not shown). On the other hand, few colonies growing on increased vancomycin concentrations (i.e. 4 and 8 mg/L) appeared in untreated control animals (one of four rats killed after 2 days of infection and two of two rats killed after 5 days of infection; marked in black in Figure 2 ), when their vegetation counts reached ≥11 log 10 cfu/g, corresponding to resistance rates of 10 25 to 10 27 (Figure 3a and  b) . In contrast, when population analyses were repeated after overnight regrowth in drug-free broth, no intermediate-resistant subpopulations were detected (Figure 3c and d) . Thus, putative hVISA were already detected in the vegetations of untreated rats, provided that they contained large bacterial densities ( 10 11 cfu/g) and that they were plated directly on vancomycincontaining agar without prior growth in drug-free medium.
Population analysis profiles of vegetation homogenates plated directly or indirectly on vancomycin-containing agar
After 2 days of vancomycin treatment the frequency of such intermediate-resistant subpopulations had increased 100-fold (corresponding to rates of 10 23 to 10
25
) when vegetation homogenates were plated directly (Figure 4a and b) . Moreover, these intermediate-resistant subpopulations persisted after treatment arrest (Figure 4b ). On the other hand, population analysis profiles returned to a vancomycin-susceptible profile when homogenates were regrown overnight in drug-free medium before testing (Figure 4c and d) .
In vitro versus in vivo persistence of vancomycin intermediate-resistant subpopulations
The observations described above indicate that the vancomycin intermediate-resistant subpopulations could persist in vivo in the absence of vancomycin pressure, but were unstable in vitro after one passage in drug-free broth. To study this in vitro/in vivo discrepancy further, the vancomycin-susceptible M1V2 and its VISA derivative M1V8 ( Figure 1) were inoculated in vitro and in vivo in drug-free conditions and the bacterial resistance phenotypes were followed over time.
For in vitro experiments, 10 6 cfu of both M1V2 and VISA M1V8 were inoculated in 10 mL of drug-free BHI and incubated with shaking at 378C for 15 days. At several timepoints, samples of the cultures were serially diluted and plated on both plain agar and plates containing 4 or 8 mg/L vancomycin. Figure 5(a) shows that bacterial counts on plain agar were stable over the entire period of time. In contrast, in the VISA M1V8 the proportion of bacteria able to grow on 4 or 8 mg/L vancomycin declined progressively by up to 4 log 10 cfu.
For in vivo tests, rats with sterile aortic vegetations were inoculated with 10 times the ID 90 of either strain and were killed at various times over a follow-up period of 7 days. Their vegetations were processed as described and plated directly on plain agar and on plates containing 4 or 8 mg/L vancomycin. As for in vitro cultures, the entire populations persisted when assessed on plain agar. On the other hand, the proportion of intermediate-resistant colonies of VISA M1V8 remained stable through the 7 days of follow up (Figure 5b) . These experiments further suggest that some in vivo conditions may promote the stability and persistence of hVISA and VISA subpopulations.
Discussion
The capacity of vancomycin therapy to select for hVISA and their detection were investigated in rats with experimental endocarditis due to a vancomycin-susceptible MRSA. Several interesting VISA detection in S. aureus experimental endocarditis 655 JAC observations were made. First, using population analysis as the screening method, we demonstrated that treatment of vancomycin-susceptible MRSA with vancomycin at doses simulating human kinetics resulted in the selection of hVISA in animals with infective endocarditis. This occurred in spite of the fact that serum concentrations of vancomycin (mean peak and trough concentrations of vancomycin in the serum of 42.2 and 8.8 mg/L, respectively) were constantly above the MIC for the infecting organism (no growth above 4 mg/L in population analysis). Moreover, the selected hVISA were associated with vancomycin treatment failure. Second, hVISA could be detected in infected vegetations only if population analysis was performed directly from the homogenate. Population analysis done after a single passage of the tissue in drug-free broth, simulating the conditions in the laboratory when processing clinical specimens, resulted in the disappearance of the hVISA phenotype. This could have occurred by spontaneous reversion of the phenotype to that of the susceptible parent strain by a dilution effect upon subculture in drug-free medium, as observed previously. 37 When hVISA colonies from infected vegetations were picked from plates containing 8 mg/L vancomycin, regrown in drug-free broth and retested for their susceptibility to vancomycin, the MIC of the drug for the test organism was 2 mg/L, thus formally considered as susceptible (data not shown). This further indicates that even the confirmation as hVISA of S. aureus colonies growing on plates supplemented with vancomycin could be problematic if standard susceptibility techniques requiring dilution are used.
S. aureus colonies growing on plates containing 8 mg/L vancomycin were also recovered from some vegetations of animals left untreated throughout the experiment (2 -5 days), provided that they had high ( 11 log 10 cfu/g) vegetation bacterial titres. The emergence of glycopeptide-resistant subpopulations in the absence of antibiotic pressure has been reported in a rat model of chronic tissue cage infection with S. aureus, when high bacterial densities were reached at the infected site, 38 as well in humans. 39 This 'inoculum' effect was also apparent in population analysis performed in vitro, when bacterial densities of strain M1V2 reached 11 log 10 cfu/mL. In contrast, the proportion of hVISA was greatly increased in vancomycin-treated animals, and resistant variants grew readily from vegetations containing much lower bacterial densities (9 -10 log 10 cfu/g) and at 100-fold higher frequency. This suggests that rare S. aureus cells expressing the heterogeneous vancomycin resistance trait pre-existed at very low, and thus undetectable, frequencies before antibiotic treatment, and were readily selected by vancomycin therapy. It has been proposed that inoculation of vancomycincontaining plates with heavy bacterial densities (11 log 10 cfu) could result in vancomycin absorption by bacterial cell walls, thus allowing the growth of colonies that were not genuinely resistant to the drug. 40 This was not likely to be the case in the present study, and should alert investigators against the reassuring impression of rare false-positive resistance phenotypes when using large inocula. It is more likely that these rare phenotypes represent genuine heteroresistant variants that are hard to isolate, especially when regrown in drug-free medium during the isolation process, because they become overgrown by susceptible populations. These data, however, may potentially be influenced by different variables. First, the bacterium used in these experiments had an agr type II background, which has been shown to be more prone to develop glycopeptide heteroresistance than other agr types. 35, 36 Whether such pre-existing cells are also present in other agr groups remains to be clarified. Second, the presence of a heterogeneous subpopulation with intermediate resistance to vancomycin is more likely in MRSA with vancomycin MIC of 2 mg/L than in MRSA with vancomycin MIC of ≤1 mg/L. 41 Finally, another important observation of the present experiments was that the hVISA subpopulations selected during vancomycin therapy persisted in vivo in the absence of antibiotic pressure. Indeed, while hVISA disappeared after one passage on drug-free media, they could readily persist in the vegetations, in the absence of vancomycin selection, for at least 3 days after the arrest of therapy. The contrast between the instability of the hVISA phenotype in prolonged liquid culture in vitro and their persistence in vivo is unexplained. After inoculation, the organisms grew to the stationary phase in both conditions ( Figure 5 ). Thereafter, in vitro cultures tended to lose viable counts and hVISA decreased more rapidly than susceptible cells, whereas in vivo cultures remained stable and kept their original proportion of total cfu and hVISA subpopulations. A major characteristic of VISA strains is cell wall thickening, which is related to an activated cell wall biosynthetic pathway and nutrient transport system. 42 It has been suggested that cell wall thickness in hVISA depends on the concentrations of nutrients in the environment. 42 Therefore, one can hypothesize that the progressive disappearance of hVISA in vitro is associated with deprivation of the culture medium of metabolites necessary for cell wall synthesis. In contrast, in vivo, nutrients would always be available to construct a thick cell wall, thus maintaining the expression of the hVISA phenotype. Alternatively, hVISA could persist in vivo using the same strategy as that used by small colony variants VISA detection in S. aureus experimental endocarditis 657 JAC (SCVs) of S. aureus. Previous studies have suggested that SCVs of S. aureus display slow growth and reduced haemolytic activity. 43 As a consequence, they have a lower ability to induce cell lysis and are able to persist intracellularly, where they are protected from the host's defences. 43, 44 Like SCVs, hVISA are characterized by their slow growth and reduced haemolytic activity. 4 Moreover, hVISA may produce increased expression of fibronectin-binding proteins, which are known to promote endothelial uptake. 45, 46 Thus, hVISA could easily enter the endothelial cell, which would provide a niche for their survival.
Detection of hVISA is difficult and different methods and protocols have been proposed to recognize them. 4 The present results indicated that vancomycin induced the emergence of hVISA in vivo, but also that appropriate culture techniques, i.e. spreading infected organs directly on drug-containing media, should be used to detect them. Thus, we provide an additional explanation for the elusive nature of hVISA strains in the diagnostic laboratory, where the clinical samples, and even the colonies growing on vancomycin-containing agar plates, are usually subcultured in drug-free medium before processing for susceptibility tests. These results suggest that, in humans, therapeutic failures with vancomycin against supposedly susceptible S. aureus infection could indeed be the result of hVISA selected during therapy but remaining undiagnosed. Moreover, the present experiments also indicated that the hVISA phenotype is stable in vivo in the absence of antibiotic pressure. These findings are clinically relevant because if hVISA are undetected in vitro while they persist in the host, continuing vancomycin therapy might promote the selection of more resistant, stable VISA in patients.
The search for potential markers that are specifically expressed by hVISA strains regardless of their genetic background is warranted. In exploratory experiments we tested whether in situ imaging or maybe cell size determination would be of any help, using, for instance, transmission electron microscopy of infected vegetations ( Figure S1 , available as Supplementary data at JAC Online). However, although thickening of cell walls was suggested in some micrographs, it was by no means a reliable diagnostic tool due to the heterogeneity of the microbial population. Thus, other markers, which might be either phenotypic or genotypic, must be sought.
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Supplementary data
